Tango Therapeutics (TNGX) announced that the first patient has been dosed in the TNG456 Phase 1/2 trial in patients with MTAP-deleted solid tumors, with a focus on glioblastoma. TNG456 is a next-generation, brain-penetrant, MTA-cooperative PRMT5 inhibitor.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNGX:
- Tango Therapeutics: Promising Developments and Strategic Focus Justify Buy Rating
- Tango Therapeutics Extends Cash Runway Amid Clinical Progress
- Tango Therapeutics files $400M mixed securities shelf
- Tango Therapeutics sees cash runway into 1Q27
- Tango Therapeutics reports Q1 EPS (36c), consensus (35c)